Since induced pluripotent stem cells (iPSCs) were first produced in 2006 from mouse cells and in 2007 from human cells, scientists have recognized the incredible potential of the cell type, including their utility in drug and toxicology screening, disease modeling, and cellular therapy applications ranging from gene correction, to whole tissue regeneration, individualized medicine, and more. Given the financial potential of the cell type, it is important to have strategies for accessing key individuals, events, and iPSC facilities.
[Read more…]
Deal-Making within the Induced Pluripotent Stem Cell (iPS Cell) Industry
In this post, we explore seven momentous partnerships that have been formed for purposes of strengthening company dominance within the induced pluripotent stem cell (iPS cell or iPSC) industry. As you’ll discover, a major theme among the “power players” within the iPSC marketplace is non-exclusive agreements with iPS Academia Japan.
These non-exclusive agreements allow companies access to an absolutely critical iPSC patent portfolio by granting access to the patented discoveries of Dr. Shinya Yamanaka, the scientist who invented induced pluripotent stem cells in 2006.
Induced Pluripotent Stem Cell News Round-Up | July 2015
Induced pluripotent stem cells (iPSCs) represent a rapidly evolving area of stem cell science. Since the discovery of the cell type in 2006, there have been several important market events, including the first ever clinical trial in humans which launched in August of 2013 to evaluate the capacity of iPSC-derived cell sheets for their ability to restore vision in patients with wet-type macular degeneration. While this trial has since been paused due to safety concerns, it represents a major milestone in clinical progress with iPSCs.
In another recent event that reverberated throughout the stem cell research community, the Supreme Court rejected the right of the Wisconsin Alumni Research Foundation (WARF) to control patents related to iPSC derivation in a landmark patent decision issued February 2015.
Indeed, every month there are major events occurring in the iPSC sector that shift industry dynamics. Read on to get informed about the most important iPSC market events that occurred in July of 2015. [Read more…]
Price-per-Click Costs Reveal Current Levels of Market Competition for iPS Cells
Purpose of Induced Pluripotent Stem Cell (iPSC) Marketing Analysis
An important area to consider for purposes of quantifying and assessing conditions within the iPSC market is marketing costs.
Because Google now controls over 70% of online searches, Google Adwords is the single best resource available for analyzing both marketing costs and online search behavior within the induced pluripotent stem cell (iPSC) market. Specifically, this post considers marketing costs for search terms related to iPSCs, using the Google Adwords tool.
[Read more…]
Epic Year for Regenerative Medicine Investments
In the past twelve months, regenerative medicine investments gained momentum, as new and promising clinical data got released. The momentum has been growing in recent years, enabling the cell therapy and genome editing sectors to evolve into a global industry.
- « Previous Page
- 1
- …
- 181
- 182
- 183
- 184
- 185
- …
- 194
- Next Page »